{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:56:06Z","timestamp":1780638966595,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Available therapeutic strategies for cancers have developed side effects, resistance, and recurrence that cause lower survival rates. Utilizing targeted drug delivery techniques has opened up new hopes for increasing the efficacy of cancer treatment. The current study aimed to investigate the appropriate condition of primming human amniotic epithelial cells (hAECs) with paclitaxel as a dual therapeutic approach consisting of inherent anticancer features of hAECs and loaded paclitaxel. The effects of paclitaxel on the viability of hAECs were evaluated to find an appropriate loading period. The possible mechanism of hAECs paclitaxel resistance was assessed using verapamil. Afterward, the loading and releasing efficacy of primed hAECs were evaluated by HPLC. The anti-neoplastic effects and apoptosis as possible mechanism of conditioned media of paclitaxel-loaded hAECs were assessed on breast and cervical cancer cell lines. hAECs are highly resistant to cytotoxic effects of paclitaxel in 24\u00a0h. Evaluating the role of P-glycoproteins in hAECs resistance showed that they do not participate in hAECs resistance. The HPLC demonstrated that hAECs uptake\/release paclitaxel with optimum efficacy in 8000\u00a0ng\/ml treatment. Assessing the anti-proliferative effect of primed hAECs condition media on cancer cells showed that the secretome induced 3.3- and 4.8-times more potent effects on MCF-7 and HeLa, respectively, and enhanced the apoptosis process. These results suggest that hAECs could possibly be used as a drug delivery system for cancer treatment. Besides, inherent anticancer effects of hAECs were preserved during the modification process. Synergistic anticancer effects of paclitaxel and hAECs can be translated into clinical practice, which would be evaluated in the future studies.<\/jats:p>","DOI":"10.1038\/s41598-022-22562-w","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T09:11:54Z","timestamp":1666948314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Anti-cancer effects of human placenta-derived amniotic epithelial stem cells loaded with paclitaxel on cancer cells"],"prefix":"10.1038","volume":"12","author":[{"given":"Amirhesam","family":"Babajani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Manzari-Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roghayeh","family":"Tarasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Niknejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"22562_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2021.112023","volume":"204","author":"X Yang","year":"2022","unstructured":"Yang, X., Zhang, T., Zhang, X., Chu, C. & Sang, S. Global burden of lung cancer attributable to ambient fine particulate matter pollution in 204 countries and territories, 1990\u20132019. Environ. Res. 204, 112023. https:\/\/doi.org\/10.1016\/j.envres.2021.112023 (2022).","journal-title":"Environ. Res."},{"key":"22562_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: An overview. Int. J. Cancer 149, 778\u2013789. https:\/\/doi.org\/10.1002\/ijc.33588 (2021).","journal-title":"Int. J. Cancer"},{"key":"22562_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66, 271\u2013289 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"22562_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3332\/ecancer.2019.961","volume":"13","author":"C Pucci","year":"2019","unstructured":"Pucci, C., Martinelli, C. & Ciofani, G. Innovative approaches for cancer treatment: Current perspectives and new challenges. Ecancermedicalscience 13, 961. https:\/\/doi.org\/10.3332\/ecancer.2019.961 (2019).","journal-title":"Ecancermedicalscience"},{"key":"22562_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14656566.2020.1724284","volume":"21","author":"L Della Corte","year":"2020","unstructured":"Della Corte, L. et al. Advances in paclitaxel combinations for treating cervical cancer. Expert Opin. Pharmacother. 21, 663\u2013677 (2020).","journal-title":"Expert Opin. Pharmacother."},{"key":"22562_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111824","volume":"141","author":"M Ashrafizadeh","year":"2021","unstructured":"Ashrafizadeh, M. et al. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed. Pharmacother. 141, 111824. https:\/\/doi.org\/10.1016\/j.biopha.2021.111824 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"22562_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1471-6712.2012.01085.x","volume":"27","author":"B Pedersen","year":"2013","unstructured":"Pedersen, B., Koktved, D. P. & Nielsen, L. L. Living with side effects from cancer treatment\u2013a challenge to target information. Scand. J. Caring. Sci. 27, 715\u2013723 (2013).","journal-title":"Scand. J. Caring. Sci."},{"key":"22562_CR8","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3389\/fbioe.2020.00748","volume":"8","author":"A Babajani","year":"2020","unstructured":"Babajani, A., Soltani, P., Jamshidi, E., Farjoo, M. H. & Niknejad, H. Recent advances on drug-loaded mesenchymal stem cells with anti-neoplastic agents for targeted treatment of cancer. Front. Bioeng. Biotechnol. 8, 748. https:\/\/doi.org\/10.3389\/fbioe.2020.00748 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"22562_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40169-018-0185-6","volume":"7","author":"H Maeda","year":"2018","unstructured":"Maeda, H. & Khatami, M. Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin. Transl. Med. 7, 11\u201311. https:\/\/doi.org\/10.1186\/s40169-018-0185-6 (2018).","journal-title":"Clin. Transl. Med."},{"key":"22562_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2174\/1389450117666160401124624","volume":"19","author":"G Unsoy","year":"2018","unstructured":"Unsoy, G. & Gunduz, U. Smart drug delivery systems in cancer therapy. Curr. Drug Targets 19, 202\u2013212 (2018).","journal-title":"Curr. Drug Targets"},{"key":"22562_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/153303460500400405","volume":"4","author":"JK Vasir","year":"2005","unstructured":"Vasir, J. K. & Labhasetwar, V. Targeted drug delivery in cancer therapy. Technol. Cancer Res. Treat. 4, 363\u2013374 (2005).","journal-title":"Technol. Cancer Res. Treat."},{"key":"22562_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.900418","volume":"10","author":"K Moeinabadi-Bidgoli","year":"2022","unstructured":"Moeinabadi-Bidgoli, K., Rezaee, M., Rismanchi, H., Mohammadi, M. M. & Babajani, A. Mesenchymal stem cell-derived antimicrobial peptides as potential anti-neoplastic agents: New insight into anticancer mechanisms of stem cells and exosomes. Front. Cell Dev. Biol. 10, 900418. https:\/\/doi.org\/10.3389\/fcell.2022.900418 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"22562_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-017-0597-8","volume":"16","author":"SM Ridge","year":"2017","unstructured":"Ridge, S. M., Sullivan, F. J. & Glynn, S. A. Mesenchymal stem cells: Key players in cancer progression. Mol. Cancer 16, 31. https:\/\/doi.org\/10.1186\/s12943-017-0597-8 (2017).","journal-title":"Mol. Cancer"},{"key":"22562_CR14","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.21873\/anticanres.14284","volume":"40","author":"SY Ahn","year":"2020","unstructured":"Ahn, S. Y. The role of MSCs in the tumor microenvironment and tumor progression. Anticancer Res. 40, 3039\u20133047. https:\/\/doi.org\/10.21873\/anticanres.14284 (2020).","journal-title":"Anticancer Res."},{"key":"22562_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/1568009615666150126154151","volume":"15","author":"AI Chang","year":"2015","unstructured":"Chang, A. I., Schwertschkow, A. H., Nolta, J. A. & Wu, J. Involvement of mesenchymal stem cells in cancer progression and metastases. Curr. Cancer Drug Targets 15, 88\u201398. https:\/\/doi.org\/10.2174\/1568009615666150126154151 (2015).","journal-title":"Curr. Cancer Drug Targets"},{"key":"22562_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13287-022-02794-3","volume":"13","author":"A Babajani","year":"2022","unstructured":"Babajani, A. et al. Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation. Stem Cell Res. Ther. 13, 126. https:\/\/doi.org\/10.1186\/s13287-022-02794-3 (2022).","journal-title":"Stem Cell Res. Ther."},{"key":"22562_CR17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1634\/stemcells.2004-0357","volume":"23","author":"T Miki","year":"2005","unstructured":"Miki, T., Lehmann, T., Cai, H., Stolz, D. B. & Strom, S. C. Stem cell characteristics of amniotic epithelial cells. Stem cells 23, 1549\u20131559 (2005).","journal-title":"Stem cells"},{"key":"22562_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcyt.2013.07.005","volume":"16","author":"H Niknejad","year":"2014","unstructured":"Niknejad, H., Khayat-Khoei, M., Peirovi, H. & Abolghasemi, H. Human amniotic epithelial cells induce apoptosis of cancer cells: A new anti-tumor therapeutic strategy. Cytotherapy 16, 33\u201340 (2014).","journal-title":"Cytotherapy"},{"key":"22562_CR19","first-page":"2022","volume":"40","author":"N-H Kang","year":"2012","unstructured":"Kang, N.-H. et al. Human amniotic membrane-derived epithelial stem cells display anticancer activity in BALB\/c female nude mice bearing disseminated breast cancer xenografts. Int. J. Oncol. 40, 2022\u20132028 (2012).","journal-title":"Int. J. Oncol."},{"key":"22562_CR20","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3892\/ijo.2017.4123","volume":"51","author":"S Bu","year":"2017","unstructured":"Bu, S., Zhang, Q., Wang, Q. & Lai, D. Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGF-\u03b21-mediated cell cycle arrest. Int. J. Oncol. 51, 1405\u20131414. https:\/\/doi.org\/10.3892\/ijo.2017.4123 (2017).","journal-title":"Int. J. Oncol."},{"key":"22562_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00441-016-2364-3","volume":"363","author":"H Niknejad","year":"2016","unstructured":"Niknejad, H., Yazdanpanah, G. & Ahmadiani, A. Induction of apoptosis, stimulation of cell-cycle arrest and inhibition of angiogenesis make human amnion-derived cells promising sources for cell therapy of cancer. Cell Tissue Res. 363, 599\u2013608 (2016).","journal-title":"Cell Tissue Res."},{"key":"22562_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00549","author":"R Lim","year":"2017","unstructured":"Lim, R., Hodge, A., Moore, G., Wallace, E. M. & Sievert, W. A pilot study evaluating the safety of intravenously administered human amnion epithelial cells for the treatment of hepatic fibrosis. Front.Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2017.00549 (2017).","journal-title":"Front.Pharmacol."},{"key":"22562_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00441-020-03280-z","volume":"383","author":"F Biniazan","year":"2021","unstructured":"Biniazan, F. et al. The differentiation effect of bone morphogenetic protein (BMP) on human amniotic epithelial stem cells to express ectodermal lineage markers. Cell Tissue Res. 383, 751\u2013763 (2021).","journal-title":"Cell Tissue Res."},{"key":"22562_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-015-0140-z","volume":"6","author":"A Bonomi","year":"2015","unstructured":"Bonomi, A. et al. Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: An in vitro study. Stem Cell Res. Ther. 6, 1\u201310 (2015).","journal-title":"Stem Cell Res. Ther."},{"key":"22562_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11010045","author":"HE Marei","year":"2019","unstructured":"Marei, H. E. et al. Human olfactory bulb neural stem cells (Hu-OBNSCs) can be loaded with paclitaxel and used to inhibit glioblastoma cell growth. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics11010045 (2019).","journal-title":"Pharmaceutics"},{"key":"22562_CR26","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/aps.2018.22","volume":"39","author":"P-J Yang","year":"2018","unstructured":"Yang, P.-J. et al. Biological characterization of human amniotic epithelial cells in a serum-free system and their safety evaluation. Acta Pharmacol. Sin. 39, 1305\u20131316. https:\/\/doi.org\/10.1038\/aps.2018.22 (2018).","journal-title":"Acta Pharmacol. Sin."},{"key":"22562_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113733","volume":"171","author":"H Lin","year":"2020","unstructured":"Lin, H. et al. Overcoming taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT\/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. Biochem. Pharmacol. 171, 113733 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"22562_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11671-019-3228-z","volume":"15","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. PD-L1 monoclonal antibody-decorated nanoliposomes loaded with paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers. Nanoscale Res. Lett. 15, 1\u201313 (2020).","journal-title":"Nanoscale Res. Lett."},{"key":"22562_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/hon.2306","volume":"35","author":"A Bonomi","year":"2017","unstructured":"Bonomi, A. et al. Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system. Hematol. Oncol. 35, 693\u2013702 (2017).","journal-title":"Hematol. Oncol."},{"key":"22562_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128511","volume":"10","author":"DB Bosco","year":"2015","unstructured":"Bosco, D. B., Kenworthy, R., Zorio, D. A. & Sang, Q.-X.A. Human mesenchymal stem cells are resistant to paclitaxel by adopting a non-proliferative fibroblastic state. PLoS ONE 10, e0128511 (2015).","journal-title":"PLoS ONE"},{"key":"22562_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-018-0831-3","volume":"9","author":"H Salehi","year":"2018","unstructured":"Salehi, H. et al. Dental pulp stem cells used to deliver the anticancer drug paclitaxel. Stem Cell Res. Ther. 9, 1\u201310 (2018).","journal-title":"Stem Cell Res. Ther."},{"key":"22562_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-18862-1","volume":"8","author":"F M\u00fcnz","year":"2018","unstructured":"M\u00fcnz, F. et al. Human mesenchymal stem cells lose their functional properties after paclitaxel treatment. Sci. Rep. 8, 1\u201311 (2018).","journal-title":"Sci. Rep."},{"key":"22562_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.biopha.2017.01.118","volume":"87","author":"F Petrella","year":"2017","unstructured":"Petrella, F. et al. Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells. Biomed. Pharmacother. 87, 755\u2013758 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"22562_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028321","volume":"6","author":"A Pessina","year":"2011","unstructured":"Pessina, A. et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS ONE 6, e28321 (2011).","journal-title":"PLoS ONE"},{"key":"22562_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4149\/neo_2020_190604N486","volume":"67","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Suppression of alphavbeta6 downregulates P-glycoprotein and sensitizes multidrug-resistant breast cancer cells to anticancer drugs. Neoplasma 67, 379\u2013388 (2020).","journal-title":"Neoplasma"},{"key":"22562_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3389\/fcell.2021.655048","volume":"9","author":"DJ Guerin","year":"2021","unstructured":"Guerin, D. J., Kha, C. X. & Tseng, K.A.-S. From cell death to regeneration: rebuilding after injury. Front. Cell Develop. Biol. 9, 547 (2021).","journal-title":"Front. Cell Develop. Biol."},{"key":"22562_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13287-017-0516-3","volume":"8","author":"S Pacioni","year":"2017","unstructured":"Pacioni, S. et al. Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts. Stem Cell Res. Ther. 8, 53. https:\/\/doi.org\/10.1186\/s13287-017-0516-3 (2017).","journal-title":"Stem Cell Res. Ther."},{"key":"22562_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1517\/17425247.2016.1167037","volume":"13","author":"AT Brini","year":"2016","unstructured":"Brini, A. T. et al. Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel. Expert Opin. Drug Deliv. 13, 789\u2013798. https:\/\/doi.org\/10.1517\/17425247.2016.1167037 (2016).","journal-title":"Expert Opin. Drug Deliv."},{"key":"22562_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/03946320130260S105","volume":"26","author":"A Bonomi","year":"2013","unstructured":"Bonomi, A. et al. Adipose tissue-derived stromal cells primed in vitro with paclitaxel acquire anti-tumor activity. Int. J. Immunopathol. Pharmacol. 26, 33\u201341 (2013).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"22562_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-09175-4","volume":"7","author":"V Cocc\u00e8","year":"2017","unstructured":"Cocc\u00e8, V. et al. Drug loaded gingival mesenchymal stromal cells (GinPa-MSCs) inhibit in vitro proliferation of oral squamous cell carcinoma. Sci. Rep. 7, 1\u20138 (2017).","journal-title":"Sci. Rep."},{"key":"22562_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s13287-020-01951-w","volume":"11","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. & Lai, D. Application of human amniotic epithelial cells in regenerative medicine: A systematic review. Stem Cell Res. Ther. 11, 439. https:\/\/doi.org\/10.1186\/s13287-020-01951-w (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"22562_CR42","doi-asserted-by":"publisher","first-page":"153303382110363","DOI":"10.1177\/15330338211036318","volume":"20","author":"A Jafari","year":"2021","unstructured":"Jafari, A., Rezaei-Tavirani, M., Niknejad, H. & Zali, H. Tumor targeting by conditioned medium derived from human amniotic membrane: New insight in breast cancer therapy. Technol. Cancer Res. Treat. 20, 15330338211036318 (2021).","journal-title":"Technol. Cancer Res. Treat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22562-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T21:05:09Z","timestamp":1666991109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22562-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22562"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22562-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18148"}}